-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $276

Benzinga·08/04/2026 18:52:17
語音播報
JP Morgan analyst Jessica Fye maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $265 to $276.